MAPT and Alzheimer disease: developed another graphene‐enhanced Raman spectroscopy platform coupled with interpretable machine learning for AD biomarker screening, achieving 98% classification accuracy while identifying both known (Aβ, Tau) and novel biomarkers through SVM analysis of enhanced spectral signals.[331]